COMPASS Pathways (CMPS) is in focus after reporting that its pivotal Phase 3 COMP005 trial of COMP360 for treatment resistant depression met its primary endpoint, with statistically significant efficacy and a safety profile consistent with earlier studies.

The Phase 3 readout lands after a series of governance and capital markets updates, including new director appointments, fresh equity incentives for board members and a recent conference appearance. It also coincides with recent momentum, with a 30 day share price return of 40.02% and a 1 year total shareholder return of 188.08%, despite a 5 year total shareholder return that is down 66.88%.

If breakthrough mental health treatments are on your radar, it may also be worth scanning other high growth healthcare opportunities through a focused screener such as 39 healthcare AI stocks

With COMP360 clearing a key Phase 3 hurdle, COMPASS Pathways now trades at US$13.05 with an indicated discount to analyst targets and intrinsic value, raising the question: is this a genuine opportunity, or is future growth already priced in?

Most Popular Narrative: 40.5% Undervalued

At a last close of $13.05 against a narrative fair value of $21.92, the widely followed view frames COMPASS Pathways as materially discounted, with that gap hinging on how quickly COMP360 turns clinical progress into a commercial product.

Completion of enrollment in the COMP006 Phase III trial and the plan to use 9 week data from Part A together with 26 week COMP005 data to support a rolling NDA process could shorten the path to potential approval, which would bring revenue forward and may support earlier earnings visibility.

Curious what sits behind that timeline confidence and valuation gap? The narrative leans on assumptions about a rapid revenue ramp, shifting margins and a rich future earnings multiple. The exact mix of those levers is what drives that $21.92 fair value call.

Result: Fair Value of $21.92 (UNDERVALUED)

However, there is still meaningful execution risk, from COMP360 clearing the rest of Phase III and FDA review to potential cash burn forcing shareholder dilution if timelines slip.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

The picture so far reflects a mix of optimism about COMP360 along with clear execution and funding risks, so consider reviewing both sides promptly and decide where you stand by checking out the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with a single stock story. Use targeted screeners to surface other opportunities worth your attention.

• Spot potential upside in companies where price and quality appear to line up by scanning the 46 high quality undervalued stocks.
• Secure more dependable income streams by checking stocks highlighted in the 10 dividend fortresses.
• Prioritise resilience by reviewing companies filtered through the 63 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.